Synthesis and neuroprotective action of xyloketal derivatives in Parkinson's disease models

Marine Drugs

Volumn 11, Issue 12, 2013, Pages 5159-5189

  Li, Shichang ^a   Shen, Cunzhou ^a   Guo, Wenyuan ^a   Zhang, Xuefei ^a   Liu, Shixin ^a   Liang, Fengyin ^a   Xu, Zhongliang ^a   Pei, Zhong ^a   Song, Huacan ^a   Qiu, Liqin ^a   Lin, Yongcheng ^a   Pang, Jiyan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

C57BL 6; Caenorhabditis elegans; Parkinson's disease; Xyloketal; Zebrafish

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; DIMETHYL SULFOXIDE; NATURAL PRODUCT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; XYLOKETAL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG DESIGN; DRUG EFFICACY; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; LONGEVITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RESPIRATORY BURST; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; ZEBRA FISH;

ANIMALS; CAENORHABDITIS ELEGANS; CELL SURVIVAL; DIMETHYL SULFOXIDE; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PYRANS; REACTIVE OXYGEN SPECIES; ZEBRAFISH;

EID: 84892406484     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md11125159     Document Type: Article

References (40)

1. Dauer, W.; Przedborski, S. Parkinson's Disease: Mechanisms and Models. Neuron 2003, 39, 889-909.
2. Henchcliffe, C.; Beal, M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neuro. 2008, 4, 600-609.
3. Dexter, D.; Carter, C.; Wells, F.; Javoy-Agid, F.; Agid, Y.; Lees, A.; Jenner, P.; Marsden, C. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 1989, 52, 381-389.
4. Zhang, J.; Perry, G.; Smith, M.A.; Robertson, D.; Olson, S.J.; Graham, D.G.; Montine, T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 1999, 154, 1423-1429.
5. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53, S26-S38.
6. Cleren, C.; Yang, L.; Lorenzo, B.; Calingasan, N.Y.; Schomer, A.; Sireci, A.; Wille, E.J.; Beal, M.F. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J. Neurochem. 2008, 104, 1613-1621.
7. Quinzii, C.M.; López, L.C.; Gilkerson, R.W.; Dorado, B.; Coku, J.; Naini, A.B.; Lagier-Tourenne, C.; Schuelke, M.; Salviati, L.; Carrozzo, R. Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. FASEB J. 2010, 24, 3733-3743.
8. Ungerstedt, U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 1968, 5, 107-110.
9. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219, 979-980.
10. Liou, H.; Tsai, M.; Chen, C.; Jeng, J.; Chang, Y.; Chen, S.; Chen, R. Environmental risk factors and Parkinson's disease. Neurology 1997, 48, 1583-1588.
11. Talpade, D.J.; Greene, J.G.; Higgins, D.S., Jr.; Greenamyre, J.T. In Vivo Labeling of Mitochondrial Complex I (NADH: UbiquinoneOxidoreductase) in Rat Brain Using [3H] Dihydrorotenone. J. Neurochem. 2000, 75, 2611-2621.
12. Seniuk, N.; Tatton, W.; Greenwood, C. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 1990, 527, 7-20.
13. Muthane, U.; Ramsay, K.; Jiang, H.; Jackson-Lewis, V.; Donaldson, D.; Fernando, S.; Ferreira, M.; Przedborski, S. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in C57/bl and CD-1 mice. Exp. Neurol. 1994, 126, 195-204.
14. Ovadia, A.; Zhang, Z.; Gash, D.M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging 1995, 16, 931-937.
15. Harrington, A.J.; Hamamichi, S.; Caldwell, G.A.; Caldwell, K.A. C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease. Dev. Dyn. 2010, 239, 1282-1295.
16. Kampkötter, A.; Gombitang Nkwonkam, C.; Zurawski, R.F.; Timpel, C.; Chovolou, Y.; Wätjen, W.; Kahl, R. Effects of the flavonoids kaempferol and fisetin on thermotolerance, oxidative stress and FoxO transcription factor DAF-16 in the model organism Caenorhabditis elegans. Arch. Toxicol. 2007, 81, 849-858.
17. Zhang, L.; Jie, G.; Zhang, J.; Zhao, B. Significant longevity-extending effects of EGCG on Caenorhabditis elegans under stress. Free Radical Biol. Med. 2009, 46, 414-421.
18. Li, J.; Baud, O.; Vartanian, T.; Volpe, J.J.; Rosenberg, P.A. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc. Natl. Acad. Sci. USA 2005, 102, 9936-9941.
19. Braungart, E.; Gerlach, M.; Riederer, P.; Baumeister, R.; Hoener, M. Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings. Neurodegener. Dis. 2004, 1, 175-183.
20. Wu, X.; Liu, X.; Jiang, G.; Lin, Y.; Chan, W.; Vrijmoed, L. Xyloketal G, a novel metabolite from the mangrove fungus Xylaria sp. 2508. Chem. Nat. Compd. 2005, 41, 27-29.
21. Lin, Y.; Wu, X.; Feng, S.; Jiang, G.; Luo, J.; Zhou, S.; Vrijmoed, L.L.; Jones, E.B.; Krohn, K.; Steingrover, K.; et al. Five unique compounds: Xyloketals from mangrove fungus Xylaria sp. from the South China Sea coast. J. Org. Chem. 2001, 66, 6252-6256.
22. Wu, X.Y.; Liu, X.H.; Lin, Y.C.; Luo, J.H.; She, Z.G.; Li, H.J.; Chan, W.L.; Antus, S.; Kurtan, T.; Elsasser, B.; et al. Xyloketal F: A strong L-calcium channel blocker from the mangrove fungus Xylaria sp. (#2508) from the South China Sea coast. Eur. J. Org. Chem. 2005, 4061-4064.
23. Xu, F.; Zhang, Y.; Wang, J.; Pang, J.; Huang, C.; Wu, X.; She, Z.; Vrijmoed, L.L.P.; Jones, E.B.G.; Lin, Y. Benzofuran Derivatives from the Mangrove Endophytic Fungus Xylaria sp. (#2508). J. Nat. Prod. 2008, 71, 1251-1253.
24. Yin, W.Q.; Lin, Y.C.; She, Z.G.; Vrijmoed, L.L.P.; Jones, E.B.G. A new compound: Xyloketal H from mangrove fungus Xylaria sp. from the South China Sea Coast. Chem. Nat. Compd. 2008, 44, 3-5.
25. Chen, W.L.; Qian, Y.; Meng, W.F.; Pang, J.Y.; Lin, Y.C.; Guan, Y.Y.; Chen, S.P.; Liu, J.; Pei, Z.; Wang, G.L. A novel marine compound xyloketal B protects against oxidized LDL-induced cell injury in vitro. Biochem. Pharmacol. 2009, 78, 941-950.
26. Zhao, J.; Li, L.; Ling, C.; Li, J.; Pang, J.Y.; Lin, Y.C.; Liu, J.; Huang, R.; Wang, G.L.; Pei, Z.; et al. Marine compound Xyloketal B protects PC12 cells against OGD-induced cell damage. Brain Res. 2009, 1302, 240-247.
27. Lu, X.L.; Yao, X.L.; Liu, Z.; Zhang, H.; Li, W.; Li, Z.; Wang, G.L.; Pang, J.; Lin, Y.; Xu, Z.; et al. Protective effects of xyloketal B against MPP+-induced neurotoxicity in Caenorhabditiselegans and PC12 cells. Brain Res. 2010, 1332, 110-119.
28. Xu, Z.; Li, Y.; Xiang, Q.; Pei, Z.; Liu, X.; Lu, B.; Chen, L.; Wang, G.; Pang, J.; Lin, Y. Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen. J. Med. Chem. 2010, 53, 4642-4653.
29. Krohn, K.; Riaz, M.; Flörke, U. Synthesis of Xyloketals, Natural Products from the Mangrove Fungus Xylaria sp. Eur. J. Org. Chem. 2004, 2004, 1261-1270.
30. Pettigrew, J.D.; Bexrud, J.A.; Freeman, R.P.; Wilson, P.D. Total synthesis of (+/-)-xyloketal D and model studies towards the total synthesis of (-)-xyloketal A. Heterocycles 2004, 62, 445-452.
31. Rodriguez, R.; Adlington, R.M.; Moses, J.E.; Cowley, A.; Baldwin, J.E. A New and Efficient Method for o-Quinone Methide Intermediate Generation: Application to the Biomimetic Synthesis of (±)-Alboatrin. Org. Lett. 2004, 6, 3617-3619.
32. Krohn, K.; Riaz, M. Total synthesis of (+)-xyloketal D, a secondary metabolite from the mangrove fungus Xylaria sp. Tetrahedron Lett. 2004, 45, 293-294.
33. Pettigrew, J.D.; Freeman, R.P.; Wilson, P.D. Total synthesis of (-)-xyloketal D and its - Confirmation of absolute stereochemistry. Can. J. Chem. 2004, 82, 1640-1648.
34. Pettigrew, J.D.; Wilson, P.D. Synthesis of xyloketal A, B, C, D and G analogues. J. Org. Chem. 2006, 71, 1620-1625.
35. Pettigrew, J.D.; Wilson, P.D. Total synthesis of (-)-xyloketal A. Org. Lett. 2006, 8, 1427-1429.
36. Huang, Y.; Lin, Y.C. Concise Synthesis of Xyloketal C Analogues. Heterocycles 2009, 78, 749-755.
37. Xu, Z.; Li, Y.; Lu, B.; Pang, J.; Lin, Y. An Expedient Approach to the Benzopyran Core: Application to Synthesis of the Natural Products (±)-Xyloketals and (±)-Alboatrin. Chin. J. Chem. 2010, 28, 2441-2446.
38. Hermann, A.C.; Millard, P.J.; Blake, S.L.; Kim, C.H. Development of a respiratory burst assay using zebrafish kidneys and embryos. J. Immunol. Methods 2004, 292, 119-129.
39. Przedborski, S.; Vila, M. The 1-Methyl-4-Phenyl-1,2,3,6- Tetrahydropyridine Mouse Model. Ann. N. Y. Acad. Sci. 2003, 991, 189-198.
40. Gollnick, K.; Knutzen-Mies, K. Dye-sensitized photooxygenation of 2,3-dihydrofurans: Competing [3 + 2] cycloadditions and ene reactions of singlet oxygen with a rigid cyclic enol ether system. J. Org. Chem. 1991, 56, 4017-4027.